Which of Your pN0 Patients Might Really be pN1?
The clinical challenge with stage II patients is well known. An average of 20% of patients recur, but only 4-5% benefit from treatment. The Previstage™ GCC Colorectal Cancer Staging Test can help you determine which pN0 patients might actually be pN1 and, in turn, potentially have a higher risk of recurrence.
The Previstage GCC Colorectal Cancer Staging Test analyzes a lymph node for levels of GCC Guanylyl Cyclase C (GCC) equivalent to that found in stage III lymph nodes having metastases greater than 2mm. It does this while examining on average 375 times more lymph node tissue than histopathology, which evaluates less than 1% of a lymph node, and using technology with 100,000 times more sensitivity. These improvements increase the likelihood of accurately identifying patients at high or low risk of disease recurrence. Learn more